Shortage of HRTs FemSeven Conti and Sequi to continue until 2020

The shortage of hormone replacement therapy (HRT) patches FemSeven Conti and FemSeven Sequi is set to continue until 2020, C+D has learned.

exclusive
Femseven%20v2%20%28003%29.jpg
Source: FemSeven Conti patient information leaflet, 2017

Both estradiol products have been out of stock in the UK since the end of last year as a result of a “quality issue with regards to the adhesive that keeps patches attached to the skin”, manufacturer Theramex – which acquired the products in a divestment from Teva Pharmaceuticals in February 2018 – told C+D.

Theramex is “evaluating other sources of adhesive from alternative suppliers”, but this is a “time consuming process”, it said last week (April 26).

“We will inform clinics, hospitals [and] pharmacies when the products are available,” it added.

There are currently no other HRT products with precisely the same composition as FemSeven Conti or Sequi, the manufacturer said, and so it is unable to suggest any alternative treatments.

“We recommend patients consult their doctor for further advice on potential HRT alternatives,” Theramex said. “A decision on treatment should be made individually for each patient depending on an overall balance of indication, risk and convenience.”

FemSeven Mono is still available, the manufacturer stressed.

FemSeven Sequi and FemSeven Conti were among the HRTs on a list of 177 medicines which the National Pharmacy Association said last week have been experiencing shortages. The list also featured the HRTs Elleste Solo, Elleste Duet and Cyclo-Progynova.

Sign in or register for free

Latest from News

All the headlines: Community pharmacy funding deal

 
• By 
 • comment

Find out everything you need to know about the government’s plans for community pharmacy – as outlined in this week’s long-awaited pharmacy funding deal.

Pharmacy stop-smoking service expands to ‘non-registered’ staff

 
• By 
 • comment

The new pharmacy contract has expanded who can deliver the smoking cessation service, as well as adding the provision of two drugs via PGDs.

Revealed: 2024/25 contract cash uplift already paid

 
• By 
 • comment

Following this week’s announcement of the long-awaited pharmacy funding deal, C+D has learned that contractors have already received the additional £106 million in retrospective funding for 2024/25.

More from Business